Pre-clearance

China ／ NMPA

Advertisements for medical services, drugs and medical devices must be reviewed as to content by the advertising review authority before publication, and may not be published without such review.

医療・医薬品・医療機器等の広告は発布前に広告審査機関による内容審査を受けなければならず、審査を経ていないものは発布できない。

statuteInterim Measures for the Administration of Advertising Review of Drugs, Medical Devices, Health Foods and Foods for Special Medical Purposes (SAMR Order No. 21, 2019), articles 3-5; Advertising Law article 46checked 2026-09-23

Note
Article 4 of the Measures assigns review to the provincial-level market regulation and drug regulation departments. Advertising Law article 46 is the statutory basis and was verified at https://sjfg.samr.gov.cn/law/file/origin/3235243/1663323571058.pdf

The same topic elsewhere

Japan ── Sales information materials must be reviewed before use by an in-house promoti…United States ── An applicant must submit specimens of promotional labeling and advertising at …Canada ── Preclearance of advertising for marketed health products is administered throu…European Union ── Member States must ensure that there are adequate and effective methods to mon…United Kingdom ── The MHRA has statutory powers to require companies to submit advertising mater…Australia ── Use of a restricted representation, that is one referring to a serious form of…Korea ── A manufacturer, marketing authorisation holder or importer that intends to adv…Switzerland ── Switzerland has no across-the-board pre-vetting scheme: prior authorisation by…